BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28695630)

  • 1. A pilot phase II study of ofatumumab monotherapy for extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
    Kiesewetter B; Neuper O; Mayerhoefer ME; Dolak W; Lukas J; Simonitsch-Klupp I; Raderer M
    Hematol Oncol; 2018 Feb; 36(1):49-55. PubMed ID: 28695630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma.
    Raderer M; Jäger G; Brugger S; Püspök A; Fiebiger W; Drach J; Wotherspoon A; Chott A
    Oncology; 2003; 65(4):306-10. PubMed ID: 14707449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of low grade gastric mucosa-associated lymphoid tissue lymphoma in stage I with Helicobacter pylori eradication. Long-term results after sequential histologic and molecular follow-up.
    Montalban C; Santon A; Boixeda D; Redondo C; Alvarez I; Calleja JL; de Argila CM; Bellas C
    Haematologica; 2001 Jun; 86(6):609-17. PubMed ID: 11418369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma.
    Streubel B; Ye H; Du MQ; Isaacson PG; Chott A; Raderer M
    Oncology; 2004; 66(6):476-80. PubMed ID: 15452377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study.
    Jäger G; Neumeister P; Brezinschek R; Hinterleitner T; Fiebiger W; Penz M; Neumann HJ; Mlineritsch B; DeSantis M; Quehenberger F; Chott A; Beham-Schmid C; Höfler G; Linkesch W; Raderer M
    J Clin Oncol; 2002 Sep; 20(18):3872-7. PubMed ID: 12228207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial.
    Ferreri AJ; Sassone M; Kiesewetter B; Govi S; Scarfò L; Donadoni G; Raderer M
    Ann Oncol; 2015 Aug; 26(8):1760-5. PubMed ID: 25935794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged follow-up on lenalidomide-based treatment for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma)-Real-world data from the Medical University of Vienna.
    Kiesewetter B; Lamm W; Neuper O; Mayerhoefer ME; Simonitsch-Klupp I; Raderer M
    Hematol Oncol; 2019 Oct; 37(4):345-351. PubMed ID: 31283840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy.
    Martinelli G; Laszlo D; Ferreri AJ; Pruneri G; Ponzoni M; Conconi A; Crosta C; Pedrinis E; Bertoni F; Calabrese L; Zucca E
    J Clin Oncol; 2005 Mar; 23(9):1979-83. PubMed ID: 15668468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
    Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
    Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
    Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
    Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma.
    Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME; Raderer M
    Hematol Oncol; 2017 Jun; 35(2):177-186. PubMed ID: 26580149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type.
    Raderer M; Traub T; Formanek M; Virgolini I; Osterreicher C; Fiebiger W; Penz M; Jäger U; Pont J; Chott A; Kurtaran A
    Br J Cancer; 2001 Nov; 85(10):1462-6. PubMed ID: 11720429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
    Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
    Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective analysis of low-grade gastric malt lymphoma after Helicobacter pylori eradication.
    Hong SS; Jung HY; Choi KD; Song HJ; Lee GH; Oh TH; Jo JY; Kim KJ; Byeon JS; Myung SJ; Yang SK; Hong WS; Kim JH; Min YI
    Helicobacter; 2006 Dec; 11(6):569-73. PubMed ID: 17083379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases.
    Begum S; Sano T; Endo H; Kawamata H; Urakami Y
    J Med Invest; 2000 Feb; 47(1-2):36-46. PubMed ID: 10740978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP).
    Wöhrer S; Drach J; Hejna M; Scheithauer W; Dirisamer A; Püspök A; Chott A; Raderer M
    Ann Oncol; 2003 Dec; 14(12):1758-61. PubMed ID: 14630681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.
    Conconi A; Martinelli G; Thiéblemont C; Ferreri AJ; Devizzi L; Peccatori F; Ponzoni M; Pedrinis E; Dell'Oro S; Pruneri G; Filipazzi V; Dietrich PY; Gianni AM; Coiffier B; Cavalli F; Zucca E
    Blood; 2003 Oct; 102(8):2741-5. PubMed ID: 12842999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma.
    Chen LT; Lin JT; Tai JJ; Chen GH; Yeh HZ; Yang SS; Wang HP; Kuo SH; Sheu BS; Jan CM; Wang WM; Wang TE; Wu CW; Chen CL; Su IJ; Whang-Peng J; Cheng AL
    J Natl Cancer Inst; 2005 Sep; 97(18):1345-53. PubMed ID: 16174856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifocal extranodal mucosa-associated lymphoid tissue lymphoma affecting the larynx.
    Arndt S; Veelken H; Schmitt-Gräff A; Aschendorff A; Maier W; Richter B
    Ann Otol Rhinol Laryngol; 2007 Apr; 116(4):257-61. PubMed ID: 17491523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.
    Nückel H; Meller D; Steuhl KP; Dührsen U
    Eur J Haematol; 2004 Oct; 73(4):258-62. PubMed ID: 15347312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.